HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ-EYE Ltd. announced their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships. Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO AI-assisted lesion detection device in the U.S.A. beginning October 1, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in WashingtonD.C., U.S.A. MAGENTIQ-COLO is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies.

Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in Europe, United States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.